5 g/day (up to 10–15 g in clinical settings).
Preliminary evidence in fatigue and energy recovery; small, heterogeneous studies.
See the study (pilot trial) →⏱ 3 min read
D-ribose is a five-carbon monosaccharide (a pentose) that the body synthesizes endogenously through the pentose phosphate pathway and that forms the sugar backbone of DNA, RNA, ATP, and the enzymatic cofactors NAD, FAD, and coenzyme A; its biological role in these molecules is strictly structural: every time a cell synthesizes new ATP, nucleotides, or nucleic acids it needs ribose available, and under conditions of high demand (metabolic stress, ischemia, intense physical exertion, enzymatic defects of the pentose pathway) a supply of exogenous D-ribose could theoretically speed up regeneration of the cellular nucleotide pool.
This biochemical hypothesis underlies the use of D-ribose as a supplement in conditions where a cellular energy deficit is suspected: chronic fatigue, fibromyalgia, ischemic cardiomyopathy, myoadenylate deaminase deficiency, and, popularly, as an ergogenic aid in athletes; the available clinical data are modest but consistent with real benefits in some specific indications and with marginal or null effects in others, a variability that deserves analysis by indication.
The indication with the most interesting clinical data is fibromyalgia and chronic fatigue syndrome: an open-label pilot study published in 2006 with 41 patients showed significant and clinically relevant improvements in scales of fatigue, pain, sleep, and overall well-being with D-ribose at 5 grams three times a day for 3-4 weeks; although the open-label design (no placebo group) limits the strength of the conclusions, the findings are consistent with the mitochondrial energy deficit hypothesis proposed in these conditions.
A later retrospective study published in 2012 with 257 patients with fibromyalgia confirmed similar improvements in a larger cohort, maintaining the pattern of modest but clinically relevant effects; these data require confirmation in randomized placebo-controlled trials, which are methodologically complicated by the variability inherent in these conditions and by the difficulty of maintaining blinding with a natural sweetener.
In chronic heart failure, several small studies have shown improvements in diastolic function, exercise capacity, and quality of life with supplementation at 5-15 grams daily for 6-8 weeks; the effects are modest and the data are insufficient to incorporate it into cardiology guidelines, but they provide mechanistic support for use in selected patients with cardiomyopathy and a postulated cardiac energy deficit.
Unlike the commercial expectations generated in the 2000s, rigorous trials in healthy athletes have been disappointing: most well-designed studies have not shown significant improvements in power, strength, endurance, or recovery with D-ribose supplementation before or after training; the theoretically postulated advantages (accelerated ATP regeneration after intense exertion) do not translate into measurable clinical benefits in people with normal energy metabolism, an important lesson about the limits of extrapolating mechanisms to functional applications.
The doses studied range from 5 to 15 grams daily, split into 2-3 doses with or without food; for fibromyalgia or chronic fatigue, 5 g three times a day for 3-4 weeks as a therapeutic trial; for heart failure, 5-15 g/day divided according to the specific indication; D-ribose has a sweet, slightly fruity taste and dissolves well in water or juice.
Generally well tolerated; the most frequent adverse effects are transient hypoglycemia (especially if taken on an empty stomach or in predisposed people, because D-ribose stimulates insulin secretion without providing the metabolizable sugar equivalent to glucose), mild digestive discomfort (diarrhea with high doses), and occasional headache; people with diabetes should be especially cautious because of the effect on blood glucose and should monitor it; those taking antidiabetic drugs may experience potentiation of the hypoglycemic effect; in pregnancy and breastfeeding the data are limited and avoidance is recommended as a precaution; people with gout should avoid it because of a theoretical risk of raised uric acid from increased purine catabolism; commercial products tend to be quite expensive for a relatively simple molecule, a relevant practical consideration.
Information, not medical advice. Scientific evidence reflects the quality of the studies.